<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03825744</url>
  </required_header>
  <id_info>
    <org_study_id>HR-TPO-SAA-III</org_study_id>
    <nct_id>NCT03825744</nct_id>
  </id_info>
  <brief_title>Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia</brief_title>
  <official_title>A Phase III Multicenter Randomized Study of Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, placebo-control, phase III study to investigate
      hetrombopag in subjects with severe AA who are treated naive.

      180 treated naive patients with SAA will be enrolled in the study. The primary objective of
      the study will be the rate of complete hematologic response at six months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete hematologic response at six months.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Hetrombopag Olamine+Standard Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Standard Therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag Olamine+Standard Therapy</intervention_name>
    <description>once daily</description>
    <arm_group_label>Hetrombopag Olamine+Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo+Standard Therapy</intervention_name>
    <description>once daily</description>
    <arm_group_label>Placebo+Standard Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.15 Years to 75 Years (weight greater than 50 kg if Age &lt; 18 years old). 2.Severe aplastic
        anemia characterized by Bone marrow cell proliferation less than 25 percent (If ≥25% but
        &lt;50%, the remaining hematopoietic cells should be &lt;30%) AND At least two of the following:
        Absolute neutrophil count &lt;0.5×109/L; Platelet count &lt;20×109/L; Absolute reticulocyte count
        &lt;20×109/L.

        3.Unsuitable or unwilling to perform hematopoietic stem cell transplantation (HSCT).

        4.Signed informed consent.

        Exclusion Criteria:

          1. Diagnosis of whole blood cell reduction due to other causes or bone marrow
             hypoproliferative diseases.

          2. Subjects who have previously received immunosuppressive therapy with mycophenolate
             mofetil, sirolimus, high dose cyclophosphamide (≥45mg/kg/d), alemtuzumab, etc；or have
             treated with thrombopoietin receptor agonist (eg, eltrombopag, romiplostim, rhTPO,
             etc.) prior to randomization.

          3. Previous history of hematopoietic stem cell transplantation.

          4. Subjects who is known or suspected of contraindications or hypersensitivity to
             Hetrombopag's API (Active Pharmaceutical Ingredient).

          5. Evidence of clonal cytogenetic abnormalities at the time of screening.

          6. Bleeding and/or Infection not adequately responding to appropriate therapy.

          7. Any laboratory or clinical evidence for HIV infection. Any clinical history for
             hepatitis C infection; chronic hepatitis B infection; or any evidence for active
             hepatitis at the time of subjects screening.

          8. ALT&gt; 2.5 x upper limit of normal (ULN), AST&gt; 2.5 x upper limit of normal (ULN) DBLI&gt;
             1.5 x upper limit of normal (ULN), Scr&gt; upper limit of normal (ULN).

          9. Subjects with uncontrolled hypertension (&gt;180/100mmHg), severe arrhythmia (such as
             complete left bundle branch block, QT interval prolongation (Bazetts formula), torsade
             ventricular tachycardia, etc.), unstable angina, pulmonary hypertension at the time of
             screening.

         10. Subjects diagnosed with cirrhosis or portal hypertension.

         11. Subjects with malignant solid tumors of any organ system within 5 years prior to
             screening, with or without treatment, metastasis or recurrence, except for local
             cutaneous basal cell carcinoma; subjects with hematological tumors found previously or
             during screening.

         12. Subjects with deep vein thrombosis, myocardial infarction, stroke or peripheral
             arterial embolization within 12 months prior to randomization.

         13. Female subjects who are nursing or pregnant.

         14. Subjects cannot comply with effective contraception.

         15. Subjects have participated in other clinical trial within the 3 months prior to study
             entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ya-Qi Shen</last_name>
    <phone>+86-18036617093</phone>
    <email>shenyaqi@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blood Diseases Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengkui Zhang</last_name>
      <email>zhfk@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SAA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

